---
schema_version: "secwatch.filing_event.v1"
accession: "0000939767-23-000035"
form_type: "8-K"
ticker: "EXEL"
cik: "0000939767"
company_name: "EXELIXIS, INC."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:57:07.276714+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Exelixis files patent infringement suit against Cipla over generic CABOMETYX

## Summary
- Filed complaint in Delaware district court against Cipla for ANDA seeking approval of generic cabozantinib tablets (20/40/60 mg).
- Five patents asserted: U.S. Patents Nos. 8,877,776, 11,091,439, 11,091,440, 11,098,015, and 11,298,349, with latest expiry Feb. 10, 2032.
- Exelixis seeks injunction and order delaying any FDA approval until after patent expirations; Cipla did not challenge compound patent expiring Aug. 14, 2026.
- CABOMETYX is a key revenue driver for Exelixis; generic entry could impact sales if patents are invalidated or not infringed.

## SEC filing metadata
- accession: 0000939767-23-000035
- form_type: 8-K
- ticker: EXEL
- cik: 0000939767
- company_name: EXELIXIS, INC.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/939767/000093976723000035/0000939767-23-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/939767/000093976723000035/exel-20230316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000939767-23-000035
- JSON: https://secwatch.observer/filing/0000939767-23-000035.json
- Plain text: https://secwatch.observer/filing/0000939767-23-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.